LCM
LFCR icon

Levitt Capital Management’s Lifecore Biomedical LFCR Stock Holding History

Levitt Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-34,223
Closed -$452K – 55
2013
Q2 		$452K Buy
+34,223
New +$473K 0.78% 33

Other funds holding LFCR

GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Levitt Capital Management's LFCR Position: Q3 2013 in Review

Levitt Capital Management sold out of Lifecore Biomedical (LFCR) in Q3 2013, closing a stake of 34,223 shares — an estimated $452K sold.

Levitt Capital Management first reported a position in LFCR in Q2 2013 and held it in 1 quarter. The position peaked at $452K in Q2 2013. 125 funds tracked by Wall St. Rank hold LFCR as of Q3 2013.

  • Levitt Capital Management reported no remaining Lifecore Biomedical position as of Q3 2013 after selling out during the quarter.
  • Levitt Capital Management sold 34,223 Lifecore Biomedical shares in Q3 2013, an estimated $452K.
  • Levitt Capital Management first reported a position in Lifecore Biomedical in Q2 2013 and held it in 1 quarter.
  • Levitt Capital Management's Lifecore Biomedical position peaked at $452K in Q2 2013.
  • 125 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2013.

Based on Levitt Capital Management's 13F filing for Q3 2013, filed 16 Oct 2013.